[HTML][HTML] Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statins
A Tenenbaum, EZ Fisman, M Motro, Y Adler - Cardiovascular diabetology, 2006 - Springer
Lowering of low-density lipoprotein cholesterol with 3-hydroxy-3-methylglutaryl coenzyme A
reductase inhibitors (statins) is clearly efficacious in the treatment and prevention of …
reductase inhibitors (statins) is clearly efficacious in the treatment and prevention of …
[PDF][PDF] Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statins
A Tenenbaum, EZ Fisman, M Motro, Y Adler - Cardiovascular …, 2006 - sochob.cl
Lowering of low-density lipoprotein cholesterol with 3-hydroxy-3-methylglutaryl coenzyme A
reductase inhibitors (statins) is clearly efficacious in the treatment and prevention of …
reductase inhibitors (statins) is clearly efficacious in the treatment and prevention of …
Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statins.
A Tenenbaum, EZ Fisman, M Motro… - Cardiovascular …, 2006 - search.ebscohost.com
Lowering of low-density lipoprotein cholesterol with 3-hydroxy-3-methylglutaryl coenzyme A
reductase inhibitors (statins) is clearly efficacious in the treatment and prevention of …
reductase inhibitors (statins) is clearly efficacious in the treatment and prevention of …
Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statins
A Tenenbaum, EZ Fisman, M Motro… - Cardiovascular …, 2006 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: p> Lowering of low-density lipoprotein cholesterol
with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) is clearly …
with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) is clearly …
[PDF][PDF] Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statins
A Tenenbaum, EZ Fisman, M Motro, Y Adler - Cardiovascular Diabetology, 2006 - Citeseer
Lowering of low-density lipoprotein cholesterol with 3-hydroxy-3-methylglutaryl coenzyme A
reductase inhibitors (statins) is clearly efficacious in the treatment and prevention of …
reductase inhibitors (statins) is clearly efficacious in the treatment and prevention of …
Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statins
A Tenenbaum, EZ Fisman… - Cardiovascular …, 2006 - pubmed.ncbi.nlm.nih.gov
Lowering of low-density lipoprotein cholesterol with 3-hydroxy-3-methylglutaryl coenzyme A
reductase inhibitors (statins) is clearly efficacious in the treatment and prevention of …
reductase inhibitors (statins) is clearly efficacious in the treatment and prevention of …
Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statins.
A Tenenbaum, EZ Fisman, M Motro… - Cardiovascular …, 2006 - europepmc.org
Lowering of low-density lipoprotein cholesterol with 3-hydroxy-3-methylglutaryl coenzyme A
reductase inhibitors (statins) is clearly efficacious in the treatment and prevention of …
reductase inhibitors (statins) is clearly efficacious in the treatment and prevention of …
[PDF][PDF] Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statins
A Tenenbaum, EZ Fisman, M Motro, Y Adler - Cardiovascular …, 2006 - sochob.cl
Lowering of low-density lipoprotein cholesterol with 3-hydroxy-3-methylglutaryl coenzyme A
reductase inhibitors (statins) is clearly efficacious in the treatment and prevention of …
reductase inhibitors (statins) is clearly efficacious in the treatment and prevention of …
[PDF][PDF] Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statins
A Tenenbaum, EZ Fisman, M Motro… - Cardiovascular …, 2006 - researchgate.net
Lowering of low-density lipoprotein cholesterol with 3-hydroxy-3-methylglutaryl coenzyme A
reductase inhibitors (statins) is clearly efficacious in the treatment and prevention of …
reductase inhibitors (statins) is clearly efficacious in the treatment and prevention of …
[HTML][HTML] Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statins
A Tenenbaum, EZ Fisman… - Cardiovascular …, 2006 - cardiab.biomedcentral.com
Lowering of low-density lipoprotein cholesterol with 3-hydroxy-3-methylglutaryl coenzyme A
reductase inhibitors (statins) is clearly efficacious in the treatment and prevention of …
reductase inhibitors (statins) is clearly efficacious in the treatment and prevention of …